Druggio Logo

Druggio

Osteoporosis

Osteoporosis is a common disease characterised by a generalised reduction in bone mineral density (BMD), microarchitectural deterioration of bone tissue and an increased risk of fracture. Since BMD values fall progressively with age, the prevalence of osteoporosis increases with age. It has been estimated that approximately 50% of all women will have osteoporosis by the age of 80. Studies in twins and families indicate that genetic factors play an important role in the regulation of BMD and other determinants of osteoporotic fracture risk. Osteoporosis is a polygenic disorder, determined by the effects of several genes, each with relatively modest effects. Population-based studies and case-control studies have similarly identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor, oestrogen receptor and collagen gene. Bisphosphonates, and in some patients denosumab, are first-line drugs for osteoporosis.

Drugs that treat Osteoporosis

オスタバロ

Approval date

2021/3/23

Treats

Evenity

Approval date

2019/1/8

Treats

Bonviva

Approval date

2013/6/28

Treats

Edirol

Approval date

2011/1/21

Treats

Viviant

Made by

Pfizer

Approval date

2010/7/23

Treats

Forteo

Made by

Eli Lilly

Approval date

2010/7/23

Treats

Recalbon, Bonoteo

Approval date

2009/1/21

Treats

Zometa

Made by

Novartis

Approval date

2004/10/22

Evista

Made by

Eli Lilly

Approval date

2004/1/29

Treats

Actonel, Benet

Approval date

2002/1/17